<DOC>
	<DOCNO>NCT00019968</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Infusing melphalan directly tumor may kill tumor cell cause less damage healthy tissue . It yet know whether melphalan plus tumor necrosis factor effective melphalan alone soft tissue sarcoma . PURPOSE : Randomized phase II trial study effectiveness isolate limb perfusion melphalan without tumor necrosis factor treat patient soft tissue sarcoma arm leg .</brief_summary>
	<brief_title>Isolated Limb Perfusion Melphalan With Without Tumor Necrosis Factor Treating Patients With Soft Tissue Sarcoma Arm Leg</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , duration response , pattern recurrence overall survival patient unresectable high grade soft tissue sarcoma extremity follow isolated limb perfusion ( ILP ) use melphalan without tumor necrosis factor ( TNF ) . II . Determine application regimens neoadjuvant therapy render unresectable sarcoma resectable . III . Determine whether either regimen result durable disease control limb salvage patient multifocal unresectable high grade soft tissue sarcoma extremity patient stage IV soft tissue sarcoma symptomatic primary extremity tumor . PROTOCOL OUTLINE : This randomize study . Patients randomize 1 2 treatment arm : Arm I : Patients receive isolate limb perfusion ( ILP ) tumor necrosis factor ( TNF ) melphalan . After limb warm , TNF inject arterial line extracorporeal ILP circuit 2-3 minute begin time 0 , perfusion proceeds another 25 minute . Melphalan injected line 3-5 minute perfusion drug continue another 60 minute . Arm II : Patients receive ILP melphalan alone . Melphalan inject arterial line extracorporeal ILP circuit 3-5 minute begin approximately 30 minute initiation perfusion arm I , perfusion proceeds 60 minute . Patients potentially curable localized disease undergo definitive local resection 4-12 week follow ILP time maximum tumor response determine physical exam CT MRI . Patients microscopically positive viable tumor margin follow resection receive adjuvant external beam radiotherapy clinically indicate . If definitive local control confirm either local excision biopsy , amputation recommend absence unresectable metastatic disease . Local resection may also perform patient achieve partial response . Patients unresectable metastatic pulmonary disease undergo ILP palliative purpose undergo definitive resection . Patients follow 4-6 week , every 3 month 2 year , every 4 month thereafter absence disease progression . Patients expect undergo interval resection follow every 4 week procedure schedule . PROJECTED ACCRUAL : A total 12-40 patient ( 6-20 per arm ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically cytologically proven unresectable high grade soft tissue sarcoma extremity Measurable disease All disease must distal apex femoral triangle lower limb distal deltoid insertion upper limb Must local resection option accord consensus staff surgeon require amputation resection major nerve vascular structure control disease Metastatic disease allow patient would benefit palliative treatment primary tumor No prior limb perfusion No newly diagnose pediatric sarcoma curative potential chemotherapeutic regimen ( i.e. , newly diagnose Ewing 's sarcoma , rhabdomyosarcoma , etc . ) Prior/Concurrent Therapy Biologic therapy : At least 1 month since prior biologic therapy recover Chemotherapy : No prior melphalan At least 1 month since prior chemotherapy recover No 1 prior systemic chemotherapy regimen Endocrine therapy : Not specify Radiotherapy : At least 1 month since prior radiotherapy recover Surgery : Not specify Other : No concurrent immunosuppressive drug chronic anticoagulant temporarily discontinue Patient Characteristics Age : 15 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count great 100,000/mm3 Coagulation study within 1 second normal Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 2.0 mg/dL Cardiovascular : No severe peripheral vascular disease ( prior claudication ischemic peripheral vascular manifestation ) Other : Weight great 30 kg Not pregnant nursing Negative pregnancy test No active infection HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>adult soft tissue sarcoma</keyword>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>muscle cancer</keyword>
	<keyword>musculoskeletal cancer</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IA , IB , IIA adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage IIB adult soft tissue sarcoma</keyword>
	<keyword>stage IIB , IIC , III adult soft tissue sarcoma</keyword>
	<keyword>stage IIC adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>stage IVA adult soft tissue sarcoma</keyword>
	<keyword>stage IVB adult soft tissue sarcoma</keyword>
	<keyword>stage , adult soft tissue sarcoma</keyword>
</DOC>